Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE) Karyopharm Therapeutics Announces Oral Presentation at the
View HTML
Toggle Summary Karyopharm Advancing Neuroprotective SINE(TM) Compounds in Amyotrophic Lateral Sclerosis (ALS)
- Preclinical efficacy of SINE™ compounds validated in journal Nature publication - - Presentations of ALS abstracts at upcoming AAN and SfN meetings - - Collaborator grant funding supports Karyopharm's ALS research - NEWTON, Mass. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
View HTML
Toggle Summary Karyopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals — − Karyopharm to Receive $1 Million Upfront Payment, Then Eligible to Receive Up To $43.5 Million in Future Milestones, Plus Royalties — NEWTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Karyopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia
-- Antengene Rights Include All Human Oncology Indications for Selinexor, Eltanexor and KPT-9274, and Non-Oncology Human Indications for Verdinexor -- -- Karyopharm to Receive $12 Million (USD) Upfront; Total Deal Valued at up to $162 Million with Karyopharm Eligible to Receive up to $150 Million
View HTML
Toggle Summary Karyopharm and Collaborators Awarded Grant for ALS Research
  - Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS - - Fifth Grant Awarded in Support of KPT-350 as a Potential ALS Treatment Option - NEWTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company,
View HTML
Toggle Summary Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia
− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries — − Karyopharm to Receive ¥2.5 billion (US$22.3 Million) Upfront; Total Deal Value up to Approximately US$193.0 million with Karyopharm Eligible to Receive up to ¥19.15
View HTML
Toggle Summary Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
- Webcast Event Scheduled for Monday, December 5, 2016 at 8:15 PM PT -
View HTML
Toggle Summary Karyopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
First Study of Selinexor in Pediatric Patients
View HTML
Toggle Summary Karyopharm Announces Addition to the NASDAQ Biotechnology Index
NEWTON, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will
View HTML
Toggle Summary Karyopharm Announces Additional Orphan Designations Granted for Selinexor (KPT-330) by European Commission
Selinexor Receives Orphan Status in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma and Multiple Myeloma
View HTML